Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.

Castellino RC, Elion GB, Keir ST, Houghton PJ, Johnson SP, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 2000;45(4):345-9. Erratum in: Cancer Chemother Pharmacol 2000;46(1):84.

PMID:
10755324
2.

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

Patel VJ, Elion GB, Houghton PJ, Keir S, Pegg AE, Johnson SP, Dolan ME, Bigner DD, Friedman HS.

Clin Cancer Res. 2000 Oct;6(10):4154-7.

3.

The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl. Acad. Sci. USA 74, 5716-5720 (1977)

Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ.

Rev Med Virol. 1999 Jul;9(3):147-52; discussion 152-3. No abstract available.

PMID:
10479776
4.

Therapeutic efficacy of vinorelbine against pediatric and adult central nervous system tumors.

Hanley ML, Elion GB, Colvin OM, Modrich PL, Keir S, Adams DJ, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1998;42(6):479-82.

PMID:
9788574
5.

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.

Coggins CA, Elion GB, Houghton PJ, Hare CB, Keir S, Colvin OM, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1998;41(6):485-90.

PMID:
9554593
6.

Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft.

Hare CB, Elion GB, Colvin OM, Ali-Osman F, Griffith OW, Petros WP, Keir S, Marcelli SL, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1997;40(5):409-14.

PMID:
9272117
7.

Thiopurine biology and pharmacology.

Aarbakke J, Janka-Schaub G, Elion GB.

Trends Pharmacol Sci. 1997 Jan;18(1):3-7. No abstract available.

PMID:
9114722
8.

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.

Hare CB, Elion GB, Houghton PJ, Houghton JA, Keir S, Marcelli SL, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1997;39(3):187-91.

PMID:
8996518
9.

L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma.

Moynihan K, Elion GB, Pegram C, Reist CJ, Wellner D, Bigner DD, Griffith OW, Friedman HS.

Cancer Chemother Pharmacol. 1997;39(3):179-86.

PMID:
8996517
10.

Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta.

Moynihan K, Elion GB, Ali-Osman F, Marcelli S, Keir S, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1996;38(4):349-54.

PMID:
8674158
11.

Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma.

Castellino SM, Friedman HS, Elion GB, Ong ET, Marcelli SL, Page R, Bigner DD, Dewhirst MW.

Br J Cancer. 1995 Jun;71(6):1181-7.

12.

The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft.

Rich JN, Elion GB, Wellner D, Colvin OM, Groothuis DR, Hilton JH, Schlageter KE, Bigner DD, Griffith OW, Friedman HS.

Cancer Chemother Pharmacol. 1995;36(5):379-84.

PMID:
7634379
13.

Busulfan therapy of central nervous system xenografts in athymic mice.

Aaron RH, Elion GB, Colvin OM, Graham M, Keir S, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1994;35(2):127-31.

PMID:
7987988
14.

The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine.

Elion GB.

Ann N Y Acad Sci. 1993 Jun 23;685:400-7. No abstract available.

PMID:
8363248
15.

The quest for a cure.

Elion GB.

Annu Rev Pharmacol Toxicol. 1993;33:1-23. Review. No abstract available.

PMID:
8494337
16.

Development of a model of melphalan-induced gastrointestinal toxicity in mice.

Castellino S, Elion GB, Griffith OW, Dewhirst M, Kurtzberg J, Cattley RC, Scott P, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 1993;31(5):376-80.

PMID:
8431971
17.

Acyclovir: discovery, mechanism of action, and selectivity.

Elion GB.

J Med Virol. 1993;Suppl 1:2-6. Review.

PMID:
8245887
18.

Effects of glutathione or polyamine depletion on in vivo thermosensitization.

Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Casero RA Jr, Scott PA, Bullock N, Bigner DD, Friedman HS.

Int J Hyperthermia. 1992 Mar-Apr;8(2):199-208.

PMID:
1573309
19.

Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.

Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, Prescott DM, Bigner DD, Friedman HS.

Radiat Res. 1992 Feb;129(2):218-23.

PMID:
1734453
20.

Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.

Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Cattley RC, Bigner DD, Friedman HS.

Int J Hyperthermia. 1992 Jan-Feb;8(1):111-20.

PMID:
1545157
21.

Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine.

Hebert ME, Greenberg ML, Chaffee S, Gravatt L, Hershfield MS, Elion GB, Kurtzberg J.

Transplantation. 1991 Oct;52(4):634-40.

PMID:
1926342
22.

Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR.

Lilley ER, Elion GB, Dewhirst MW, Schold SC Jr, Blum MR, Savina PM, Laskowitz DT, Bigner DD, Friedman HS.

Cancer Res. 1991 Aug 1;51(15):3906-9.

23.

Kidney transplantation: overlooked pioneer.

Elion GB.

Science. 1991 Jan 18;251(4991):258. No abstract available.

PMID:
1987640
24.

Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.

Wang AM, Elion GB, Friedman HS, Bodell WJ, Bigner DD, Schold SC Jr.

Cancer Chemother Pharmacol. 1991;27(4):278-84.

PMID:
1998983
25.

Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.

Lilley ER, Rosenberg MC, Elion GB, Colvin OM, Bigner DD, Friedman HS.

Cancer Res. 1990 Jan 15;50(2):284-7.

PMID:
2295068
26.

Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.

Rosenberg MC, Colvin OM, Griffith OW, Bigner SH, Elion GB, Horton JK, Lilley E, Bigner DD, Friedman HS.

Cancer Res. 1989 Dec 15;49(24 Pt 1):6917-22.

27.

Nobel Lecture. The purine path to chemotherapy.

Elion GB.

Biosci Rep. 1989 Oct;9(5):509-29. Review.

PMID:
2679902
28.

The purine path to chemotherapy.

Elion GB.

Science. 1989 Apr 7;244(4900):41-7. Review.

PMID:
2649979
29.

Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.

Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC Jr, Hilton J, Bigner DD.

J Natl Cancer Inst. 1989 Apr 5;81(7):524-7.

PMID:
2921776
30.

Nobel lecture in physiology or medicine--1988. The purine path to chemotherapy.

Elion GB.

In Vitro Cell Dev Biol. 1989 Apr;25(4):321-30. No abstract available.

PMID:
2654122
31.

Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.

Skapek SX, Colvin OM, Griffith OW, Groothuis DR, Colapinto EV, Lee Y, Hilton J, Elion GB, Bigner DD, Friedman HS.

Biochem Pharmacol. 1988 Nov 15;37(22):4313-7.

PMID:
3196356
32.

Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.

Friedman HS, Skapek SX, Colvin OM, Elion GB, Blum MR, Savina PM, Hilton J, Schold SC Jr, Kurtzberg J, Bigner DD.

Cancer Res. 1988 Oct 1;48(19):5397-402.

33.

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.

Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Muhlbaier LH, Bigner DD.

Cancer Res. 1988 Aug 1;48(15):4189-95.

34.

Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.

Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS.

Cancer Res. 1988 May 15;48(10):2764-7.

35.

Historical background of 6-mercaptopurine.

Elion GB.

Toxicol Ind Health. 1986 Sep;2(2):1-9. No abstract available.

PMID:
3538499
36.

Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma.

Dranoff G, Elion GB, Friedman HS, Bigner DD.

Cancer Res. 1985 Sep;45(9):4082-6.

37.

Influence of glutamine on the growth of human glioma and medulloblastoma in culture.

Dranoff G, Elion GB, Friedman HS, Campbell GL, Bigner DD.

Cancer Res. 1985 Sep;45(9):4077-81.

38.

Selectivity--key to chemotherapy: presidential address.

Elion GB.

Cancer Res. 1985 Jul;45(7):2943-50. Review. No abstract available.

39.

Layer on layer: the Bruce F. Cain memorial Award lecture.

Hitchings GH, Elion GB.

Cancer Res. 1985 Jun;45(6):2415-20. No abstract available.

40.

An overview of the role of nucleosides in chemotherapy.

Elion GB.

Adv Enzyme Regul. 1985;24:323-34. Review.

PMID:
3915187
41.

Mercaptopurine "bioavailability".

Rundles RW, Elion GB.

N Engl J Med. 1984 Apr 5;310(14):929. No abstract available.

PMID:
6583508
42.

Identification of small DNA fragments synthesized in herpes simplex virus-infected cells in the presence of acyclovir.

McGuirt PV, Shaw JE, Elion GB, Furman PA.

Antimicrob Agents Chemother. 1984 Apr;25(4):507-9.

43.

Metabolic studies of high doses of allopurinol in humans.

Nelson DJ, Elion GB.

Adv Exp Med Biol. 1984;165 Pt A:167-70.

PMID:
6720373
44.

Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir.

Good SS, Krasny HC, Elion GB, de Miranda P.

J Pharmacol Exp Ther. 1983 Dec;227(3):644-51.

PMID:
6655561
45.

Preclinical toxicology studies with acyclovir: carcinogenicity bioassays and chronic toxicity tests.

Tucker WE Jr, Krasny HC, de Miranda P, Goldenthal EI, Elion GB, Hajian G, Szczech GM.

Fundam Appl Toxicol. 1983 Nov-Dec;3(6):579-86.

PMID:
6662300
46.

Preclinical toxicology studies with acyclovir: acute and subchronic tests.

Tucker WE Jr, Macklin AW, Szot RJ, Johnston RE, Elion GB, de Miranda P, Szczech GM.

Fundam Appl Toxicol. 1983 Nov-Dec;3(6):573-8.

PMID:
6662299
47.

Preclinical toxicology studies with acyclovir: ophthalmic and cutaneous tests.

Tucker WE Jr, Johnston RE, Macklin AW, Szot RJ, Elion GB, de Miranda P, Szczech GM.

Fundam Appl Toxicol. 1983 Nov-Dec;3(6):569-72.

PMID:
6662298
48.

Effects of acyclovir and its metabolites on hypoxanthine-guanine phosphoribosyltransferase.

Tuttle JV, Krenitsky TA, Elion GB.

Biochem Pharmacol. 1983 Oct 15;32(20):3011-5.

PMID:
6639669
49.

Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 3. Synthesis and activity of some nucleosides of 4-[(arylalkenyl)thio]pyrazolo[3,4-d]pyrimidines.

Rideout JL, Krenitsky TA, Chao EY, Elion GB, Williams RB, Latter VS.

J Med Chem. 1983 Oct;26(10):1489-94.

PMID:
6620308
50.

The biochemistry and mechanism of action of acyclovir.

Elion GB.

J Antimicrob Chemother. 1983 Sep;12 Suppl B:9-17. Review.

PMID:
6313600

Supplemental Content

Loading ...
Support Center